keyword
MENU ▼
Read by QxMD icon Read
search

paliperidone

keyword
https://www.readbyqxmd.com/read/28647739/antipsychotic-induced-dopamine-supersensitivity-psychosis-pharmacology-criteria-and-therapy
#1
Guy Chouinard, Anne-Noël Samaha, Virginie-Anne Chouinard, Charles-Siegfried Peretti, Nobuhisa Kanahara, Masayuki Takase, Masaomi Iyo
The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation...
June 24, 2017: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/28645134/-arterial-hyper-and-hypotension-associated-with-psychiatric-medications-a-risk-assessment-based-on-the-summaries-of-product-characteristics-smpcs
#2
Roland W Freudenmann, Ninja Freudenmann, Bartosz Zurowski, Carlos Schönfeldt-Lecuona, Ludwig Maier, Roland E Schmieder, Christian Lange-Asschenfeldt, Maximilian Gahr
Introduction Psychiatric medications are well-known triggers of clinically relevant blood pressure changes. Therefore, we aimed at creating ranking lists for their risk of causing arterial hyper- or hypotension. Methods We analyzed 784 Summaries of Product characteristics (SmPCs, available online from "Rote Liste" or "Gelbe Liste" websites) from 105 psychiatric medications registered in adult psychiatry in Germany and extracted the standardized reported risks of increasing or decreasing arterial blood pressure...
June 23, 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28641996/impact-of-paliperidone-palmitate-versus-oral-atypical-antipsychotics-on-health-care-resource-use-and-costs-in-veterans-with-schizophrenia-and-comorbid-substance-abuse
#3
Patrick Lefebvre, Erik Muser, Kruti Joshi, Maral DerSarkissian, Rachel H Bhak, Mei Sheng Duh, Brian Shiner, Yinong Young-Xu
PURPOSE: Almost half of all patients diagnosed with schizophrenia have a history of substance abuse (SA). However, data on treatment of schizophrenia with paliperidone palmitate (PP) among patients with comorbid SA are limited. The objective of this study was to compare all-cause and SA-related health care resource utilization and costs in veterans with schizophrenia and co-occurring SA who were treated with PP versus oral atypical antipsychotics (OAAs). METHODS: Veterans Health Administration electronic health record data were used to conduct a retrospective longitudinal study in veterans with schizophrenia who initiated PP or OAA between January 1, 2010 and June 30, 2016, had ≥12 months of enrollment before treatment initiation (baseline), were diagnosed with SA, and had ≥1 Global Assessment of Functioning score during baseline...
June 19, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28640988/does-half-life-matter-after-antipsychotic-discontinuation-a-relapse-comparison-in-schizophrenia-with-3-different-formulations-of-paliperidone
#4
Peter J Weiden, Edward Kim, Jason Bermak, Ibrahim Turkoz, Srihari Gopal, Joris Berwaerts
OBJECTIVE: To evaluate the effect of 1 oral and 2 distinct long-acting injectable (LAI) formulations of the same antipsychotic on times to relapse following medication discontinuation. METHODS: Data were drawn from 3 similarly designed, multicenter, double-blind, placebo-controlled, randomized-withdrawal studies of paliperidone in adults with a schizophrenia diagnosis (according to DSM-IV criteria for ≥ 1 year before screening): once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M)...
June 20, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28636569/diabetic-ketoacidosis-associated-with-antipsychotic-drugs-case-reports-and-a-review-of-literature
#5
Antonia Vuk, Martina Rojnic Kuzman, Maja Baretic, Martina Matovinovic Osvatic
BACKGROUND: Second generation antipsychotics (SGAs) are associated with metabolic disturbances. Diabetic ketoacidosis (DKA) is a rare, but potentially fatal sign of acute glucose metabolism dysregulation linked to the use of SGAs. The aims of this article are to present patients with a history of psychotic disorders and of severe metabolic diabetic ketoacidosis, possibly associated with the use of antipsychotics, and to review the current literature on the topic of antipsychotic-induced DKA...
June 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28628827/evolutionary-conservation-of-influenza-a-pb2-sequences-reveals-potential-target-sites-for-small-molecule-inhibitors
#6
Hershna Patel, Andreas Kukol
The influenza A basic polymerase protein 2 (PB2) functions as part of a heterotrimer to replicate the viral RNA genome. To investigate novel PB2 antiviral target sites, this work identified evolutionary conserved regions across the PB2 protein sequence amongst all sub-types and hosts, as well as ligand binding hot spots which overlap with highly conserved areas. Fifteen binding sites were predicted in different PB2 domains; some of which reside in areas of unknown function. Virtual screening of ~50,000 drug-like compounds showed binding affinities of up to -10...
June 16, 2017: Virology
https://www.readbyqxmd.com/read/28626271/long-acting-injectable-paliperidone-palmitate-a-review-of-efficacy-and-safety
#7
Matthew T Morris, Sandip P Tarpada
OBJECTIVE: Summarize and synthesize the current literature regarding long-acting injectable paliperidone palmitate for the treatment of schizophrenia. METHODS: A literature search of PubMed, Embase, and Web of Science was conducted in February 2016, using the following search terms in varying permutations: schizophrenia; antipsychotic medication; long-acting injectable; paliperidone palmitate; 3-monthly injectable. RESULTS: Once-monthly injectable paliperidone palmitate (PDP) has demonstrated comparable efficacy as 1st-generation long-acting injectable antipsychotics (LAIAs) in reducing disease severity and re-hospitalizations in schizophrenic patients...
May 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28614899/determination-of-plasma-concentration-reference-ranges-for-risperidone-and-paliperidone
#8
Julia Korell, Bruce Green, Bart Remmerie, An Vermeulen
Schizophrenia is a common disease managed by a range of interventions with the primary treatment being antipsychotic medications (APS). Inadequate response, lack of adherence, and/or adverse events often prevent optimal therapeutic effects or therapeutic efficiency. Monitoring APS plasma concentrations can be used together with a full clinical evaluation to help improve patient care or offer better treatment options for the patient. To enable interpretation of individual risperidone and paliperidone plasma concentrations, we developed 'reference ranges', which consider the expected variability in plasma concentrations between subjects across the population, rather than representing a 'therapeutic range' that relates to efficacy and/or safety outcomes...
June 14, 2017: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/28614404/treatment-continuation-of-four-long-acting-antipsychotic-medications-in-the-netherlands-and-belgium-a-retrospective-database-study
#9
Flore Decuypere, Jan Sermon, Paul Geerts, Tom R Denee, Cedric De Vos, Bart Malfait, Mark Lamotte, Cornelis L Mulder
Achieving greater continuation of treatment is a key element to improve treatment outcomes in schizophrenia patients. However, reported treatment continuation can differ markedly depending on the study design. In a retrospective setting, treatment continuation remains overall poor among patients using antipsychotics. This study aimed to document the difference in treatment continuation between four long-acting injectable antipsychotics based on the QuintilesIMS LRx databases, national, longitudinal, panel based prescription databases of retail pharmacies, in the Netherlands and Belgium...
2017: PloS One
https://www.readbyqxmd.com/read/28601497/comparison-of-long-acting-and-oral-antipsychotic-treatment-effects-in-patients-with-schizophrenia-comorbid-substance-abuse-and-a-history-of-recent-incarceration-an-exploratory-analysis-of-the-pride-study
#10
H Lynn Starr, Jason Bermak, Lian Mao, Steve Rodriguez, Larry Alphs
INTRODUCTION: Comorbid substance abuse is known to blunt response to treatment for underlying psychiatric disorders, but it has not been investigated in schizophrenia when comparing the effects of long-acting injectable antipsychotics with those of oral antipsychotics. METHODS: This exploratory analysis compared once-monthly paliperidone palmitate (PP1M) with daily oral antipsychotics on time to treatment failure in patients with schizophrenia and a history of incarceration...
June 7, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28594264/treatment-response-and-tolerability-with-once-monthly-paliperidone-palmitate-initiated-shortly-after-hospital-admission-in-patients-with-schizophrenia
#11
Ludger Hargarter, Marjolein Lahaye, Pierre Cherubin, Martin Lambert, Marnina Swarz, Gali Joldygulov, Flavio Vischia, Veronica Chomskaya, Vasilis P Bozikas, Eva-Maria Tsapakis, Andreas Schreiner
OBJECTIVES: Partial or non-adherence in patients with schizophrenia is common and increases the risk of relapse. This study explored safety, tolerability and treatment outcomes in patients hospitalised for an exacerbation of schizophrenia initiated on maintenance treatment of once-monthly paliperidone palmitate (PP1M). METHODS: A 6-week, observational cohort study of patients initiated on PP1M within 3 weeks after hospital admission. RESULTS: Overall, 367 patients were documented, 85...
June 8, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28593216/real-world-effectiveness-of-antipsychotic-treatments-in-a-nationwide-cohort-of-29%C3%A2-823-patients-with-schizophrenia
#12
Jari Tiihonen, Ellenor Mittendorfer-Rutz, Maila Majak, Juha Mehtälä, Fabian Hoti, Erik Jedenius, Dana Enkusson, Amy Leval, Jan Sermon, Antti Tanskanen, Heidi Taipale
Importance: It has remained unclear whether there are clinically meaningful differences between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing to the impossibility of including large unselected patient populations in randomized clinical trials, as well as residual confounding from selection biases in observational studies. Objective: To study the comparative real-world effectiveness of antipsychotic treatments for patients with schizophrenia...
June 7, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28580230/the-use-of-long-acting-injectable-antipsychotics-in-schizophrenia
#13
REVIEW
Seiya Miyamoto, W Wolfgang Fleischhacker
Schizophrenia is a mostly chronic mental disorder, and symptomatic relapse is frequently observed. It is often associated with social and/or occupational decline that can be difficult to reverse. Most patients with the illness need long-term pharmacological treatment, and antipsychotic drugs represent the mainstay of clinical care. Long-acting injectable antipsychotics (LAIs) are an important alternative to oral medication, particularly advantageous in the context of compliance management. Several new-generation antipsychotics (NGAs), including risperidone, olanzapine, paliperidone, and aripiprazole, have become available as long-acting formulations, and new evidence has been accumulating...
2017: Current Treatment Options in Psychiatry
https://www.readbyqxmd.com/read/28576133/adherence-healthcare-resource-utilization-and-medicaid-spending-associated-with-once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotic-treatment-among-adults-recently-diagnosed-with-schizophrenia
#14
Dominic Pilon, Erik Muser, Patrick Lefebvre, Rhiannon Kamstra, Bruno Emond, Kruti Joshi
BACKGROUND: Once-monthly paliperidone palmitate (PP1M) is a long-acting injectable antipsychotic that may increase adherence rates, reduce hospitalizations, and lower medical costs compared to oral atypical antipsychotics (OAAs) among schizophrenia patients. However, the impact of PP1M in recently diagnosed patients remains unknown. The present study compared adherence, healthcare resource utilization and Medicaid spending between schizophrenia patients initiating PP1M versus OAA, among patients recently diagnosed (defined using ages 18-25 years as a proxy) and among the overall population...
June 2, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28571119/item-response-theory-to-quantify-longitudinal-placebo-and-paliperidone-effects-on-panss-scores-in-schizophrenia
#15
Elke H J Krekels, Ana M Novakovic, An M Vermeulen, Lena E Friberg, Mats O Karlsson
As biomarkers are lacking, multi-item questionnaire-based tools like the Positive and Negative Syndrome Scale (PANSS) are used to quantify disease severity in schizophrenia. Analyzing composite PANSS scores as continuous data, discards information and violates the numerical nature of the scale. Here, a longitudinal analysis based on item response theory (IRT) is presented using PANSS data from Phase 3 clinical trials. Latent disease severity variables were derived from item-level data on the positive, negative and general PANSS subscales each...
June 1, 2017: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/28553116/comparative-efficacy-and-safety-of-antipsychotics-in-the-treatment-of-schizophrenia-a-network-meta-analysis-in-a-japanese-population
#16
Taro Kishi, Toshikazu Ikuta, Shinji Matsunaga, Yuki Matsuda, Kazuto Oya, Nakao Iwata
BACKGROUND: The relative efficacy and tolerability of antipsychotics for schizophrenia are considerably well studied. This study aimed to examine whether previous findings could be replicated in a genetically distinct and homogenous group (ie, Japanese patients with schizophrenia) and whether previous findings could be extended to a broader range of antipsychotics with previously unclear relative efficacy and tolerability. METHODS: Bayesian network meta-analysis was performed in which randomized trials comparing any of the following interventions were included: second-generation antipsychotics, haloperidol, or placebo...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28540038/effectiveness-of-paliperidone-depot-injection-in-seriously-violent-men-with-comorbid-schizophrenia-and-dissocial-personality-disorder-in-a-uk-high-security-hospital
#17
Anna-Marie Mortlock, Fintan Larkin, Callum C Ross, Nitin Gupta, Samrat Sengupta, Mrigendra Das
BACKGROUND: High-security hospital patients are often complex in presentation and are characterized by treatment resistance, medication nonadherence and history of violence. Paliperidone is licensed both as an oral and depot antipsychotic medication in the treatment of schizophrenia. Clinical trials have shown that paliperidone depot is well tolerated with similar efficacy to risperidone depot but with additional practical advantages. Whilst data exist for the effectiveness of paliperidone palmitate (PP), there are no studies involving patients in forensic settings or those with comorbid personality disorder...
May 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28486258/placental-transfer-of-paliperidone-during-treatment-with-a-depot-formulation
#18
Raymond Binns, Sean J OʼHalloran, Stephanie Teoh, Kate Doherty, David A Joyce
No abstract text is available yet for this article.
May 8, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28478683/hyponatremia-associated-with-once-monthly-paliperidone-palmitate-use
#19
(no author information available yet)
No abstract text is available yet for this article.
May 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28465867/differences-in-antipsychotic-related-adverse-events-in-adult-pediatric-and-geriatric-populations
#20
Hersh Sagreiya, Yi-Ren Chen, Narmadan A Kumarasamy, Karthik Ponnusamy, Doris Chen, Amar K Das
In recent years, antipsychotic medications have increasingly been used in pediatric and geriatric populations, despite the fact that many of these drugs were approved based on clinical trials in adult patients only. Preliminary studies have shown that the "off-label" use of these drugs in pediatric and geriatric populations may result in adverse events not found in adults. In this study, we utilized the large-scale U.S. Food and Drug Administration (FDA) Adverse Events Reporting System (AERS) database to look at differences in adverse events from antipsychotics among adult, pediatric, and geriatric populations...
February 26, 2017: Curēus
keyword
keyword
32835
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"